Literature DB >> 2859501

Double-blind short-term trial of furazolidone in peptic ulcer.

Z T Zheng, Z Y Wang, Y X Chu, Y N Li, Q F Li, S R Lin, Z M Xu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859501

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

1.  Treatment of duodenal ulceration with Furazolidine in China preceded the discovery of its association with H pylori.

Authors:  Frank-Ivor Tovey
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

2.  Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.

Authors:  M Tavakoli; A T Prach; M Malek; D Hopwood; B W Senior; F E Murray
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

Review 3.  Helicobacter pylori in gastroduodenal disease.

Authors:  R J Loffeld
Journal:  Pharm Weekbl Sci       Date:  1990-04-27

Review 4.  Campylobacter pyloridis, gastritis, and peptic ulceration.

Authors:  C S Goodwin; J A Armstrong; B J Marshall
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

5.  Reduction of gastric ulcer recurrence after suppression of Helicobacter pylori by cefixime.

Authors:  M Tatsuta; H Ishikawa; H Iishi; S Okuda; Y Yokota
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

6.  Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.

Authors:  Hong Cheng; Fu-Lian Hu
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

7.  Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone.

Authors:  G Bianchi Porro; F Parente; M Lazzaroni
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

8.  Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy.

Authors:  Zaigham Abbas; Javed Yakoob; Shahab Abid; Wasim Jafri; Muhammad Islam; Zahid Azam; Imran Hilal
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

9.  Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis.

Authors:  J I Wyatt; B J Rathbone; M F Dixon; R V Heatley
Journal:  J Clin Pathol       Date:  1987-08       Impact factor: 3.411

Review 10.  Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.

Authors:  Hong Lu; Wei Zhang; David Y Graham
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-10       Impact factor: 2.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.